Teresa Maria Caimi

Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

F. Baudo

Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

R. Redaelli

Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

F Cataldo

European Institute of Oncology

G Mostarda

Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

Francesco Decataldo

University of Bologna

Annarita Tagliaferri

University of Parma

Enrica Morra

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Anna Rosa Corno

Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

Cristina Santoro

Policlinico Umberto I

Pier Mannuccio Mannucci

University of Milan

Cooperative Institutions

KLE Society Hospital

1,386

Sir Ganga Ram Hospital

1,355

University College London

378

Thrombosis Research Institute

371

St George's, University of London

Bayer (Germany)

OLVG

McMaster University

Harvard University

Brigham and Women's Hospital

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Diagnosis and treatment of acquired haemophilia

Haemophilia (2010)

F. Baudo Teresa Maria Caimi F Cataldo

Acquired haemophilia (AH) is an autoimmune syndrome characterized by acute bleeding in patients with negative family and personal history, and factor VIII depletion. Its incidence is 1.6 x 106 population per year. AH is associated with autoimmune diseases, solid tumours, lymphoprolipherative diseases, pregnancy; 50% of the cases idiopathic. Spontaneous or after minor trauma severe bleeding associated with a prolonged activated partial thromboplastin time, not corrected by incubation with normal plasma, with a normal prothrombin time are the diagnostic hallmarks. The goals of management are the control of bleeding and the suppression of inhibitor. First-line haemostatic treatment includes recombinant factor VIIa and activated prothrombin complex concentrate. Prednisone +/- cyclophosphamide and other immunosuppressive agents are the standard intervention for inhibitor eradication.

Recombinant Factor VIIa

10.1111/j.1365-2516.2010.02232.x

Cite

Citations (65)

Critical bleeding in pregnancy: a novel therapeutic approach to bleeding.

PubMed (2006)

F. Baudo Teresa Maria Caimi G Mostarda F Cataldo Edward A. Morra

In the developed countries the frequency of life threatening post-partum hemorrhages (PPH) is 1 in 1,000 deliveries with a risk of death of 1-2/100,000 deliveries. Hysterectomies for intractable bleeding are carried out in approximately 50% of the cases. The majority of PPH have obstetrical causes, most frequently atony of the uterus. Hereditary and acquired hemostatic defects are very rare. Guidelines of standard surgical and medical measures are available. In this paper we focus on the use of activated recombinant factor VII (rFVIIa) in PPH.A computerized literature search was carried out in PubMed and Ovid for papers published between 2001 and 2005 in the English literature reporting on life-threatening PPH treated with rFVIIa after failure of conventional therapy, including hysterectomy.We identified 11 papers including 39 patients; in 18 of them the laboratory data were indicative for disseminated intravascular coagulation and in 24 hysterectomy was carried out. Controlled or reduced bleeding was reported in 38 out of 39 treated patients.The bleeding can occur in a series of events conductive to metabolic complications, hypoxia, disseminate intravascular coagulation, organ damage and multiorgan failure, progressively exhaustive. The therapeutic intervention must be instituted as early as possible before successive complications ensue. These preliminary reports in PPH after failure of conventional standard therapy suggest that rFVIIa is an active agent but should be administered as early as possible before the consequences of severe and intractable bleeding.

Uterine atony

Severe bleeding

Major bleeding

Post partum

Therapeutic approach

Source

Cite

Citations (18)

Antithrombin III (ATILL) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study

Intensive Care Medicine (1998)

F. Baudo Teresa Maria Caimi Francesco Decataldo A. Ravizza Sergio Arlati

10.1007/s001340050576

Cite

Citations (233)

Treatment of DIC with Antithrombin III in Patients Admitted to Intensive Care Units

Springer eBooks (1999)

F. Baudo F Cataldo Teresa Maria Caimi Giliola Calori

Coagulation system

10.1007/978-3-642-60239-9_7

Cite

Citations (0)

Cyclosporine therapy in refractory/relapsed patients with thrombotic thrombocytopenic purpura

American Journal of Hematology (2009)

Annamaria Nosari R. Redaelli Teresa Maria Caimi Gianni Mostarda Enrica Morra

Hematology

10.1002/ajh.21385

Cite

Citations (28)

ATIH TREATMENT IN PATIENTS (PTS) REQUIRING HEMODINAMYC (H) AND RESPIRATORY (R) SUPPORT (S)

Shock (1997)

F. Baudo Armando D’Angelo Teresa Maria Caimi Francesco Decataldo A. Ravizza

Baudo, F.; D'Angelo, A.; Caimi, T M; deCataldo, F.; Ravizza, A.*; Casella, G.*; Carugo, D.*; Arlati, S*; Palareti, G.; Legnani, C.; Ridolfi-L, #; Rossi, R.#; Crippa, L.; Guidici, D.§; Gallioli, G.§; Wolfler, A.§; Calori, G^ Author Information

10.1097/00024382-199703001-00663

Cite

Citations (0)

Rate and appropriateness of polypharmacy in older patients with hemophilia compared with age‐matched controls

Haemophilia (2018)

Pier Mannuccio Mannucci Alessandro Nobili Emanuela Marchesini Emily Oliovecchio Laura Cortesi

Background In older people, multiple chronic ailments lead to the intake of multiple medications (polypharmacy) that carry a number of negative consequences (adverse events, prescription and intake errors, poor adherence, higher mortality). Because ageing patients with haemophilia (PWHs) may be particularly at risk due to their pre‐existing multiple comorbidities (arthropathy, liver disease), we chose to analyse the pattern of chronic drug intake in a cohort of PWHs aged 60 years or more. Patients and methods S + PHERA is a multicentre observational study, with the broad goal to evaluate prospectively the health status and medication intake in 102 older patients with severe haemophilia A or B compared with 204 age‐ and residence‐matched controls chosen randomly from the same general practices of PWHs. The rate of potential drug‐drug interactions (PDDI) was evaluated as a proxy of prescription appropriateness. Results After excluding replacement therapies and antiviral drugs, PWHs took in average less daily drugs than controls (2.4 ± 2.5 vs 3.0 ± 2.4) and had a lower rate of polypharmacy. Moreover, their prevalence of PDDI was lower (16.7% vs 27%). Conclusions The rate of polypharmacy and the appropriateness of medications other than those for haemophilia and related comorbidities are acceptable in Italian PWHs, and better than those in their age peers without haemophilia, perhaps owing to drug tailoring and deprescribing by the specialized haemophilia centres at the time of regular visits. However, the PWHs investigated herewith were relatively young and the rate of polypharmacy and related PDDIs may become more prominent and crucial when older ages are reached, suggesting the need of continuous surveillance on prescribed drugs and the risk of drug‐drug interactions.

Deprescribing

10.1111/hae.13595

Cite

Citations (7)

Management of High Haemorragic Risk Surgery: A Case of Acquired von Willebrand Disease (AVWD).

Blood (2007)

G Mostarda Anna Maria Cafro Teresa Maria Caimi R. Redaelli Anna Rosa Corno

Desmopressin

Bleeding diathesis

von Willebrand Disease

Fresh frozen plasma

Bleeding time

10.1182/blood.v110.11.3950.3950

Cite

Citations (0)

The impact of antiviral therapy with zidovudine: A retrospective study on HIV-positive hemophiliacs in Italy

Haematologica (1995)

Romano Arcieri Maria Puopolo F. Baudo Flavia Chiarotti Vincent DeRosa

Background. The effects of zidovudine (ZDV) treatment on progression to AIDS are not completely clear. This study evaluated the effects of ZDV treatment on the progression to AIDS in HIV-positive hemophiliacs. Methods. A retrospective study ws carried out on HIV-infected hemophiliacs: it included 238 individuals, 119 each from the treated and the non-treated groups. For the group receiving ZDV, we included those for whom a CD4 count was available prior (median = 1 month) to beginning therapy. The cumulative incidence of developing AIDS was estimated by the Kaplan-Meier method. To identify factors independently associated with progression to AIDS, a Cox proportional hazards model was used. Results. The cumulative incidence of developing AIDS at 8 years after HIV seroconversion was 10.4% [standard error (SE)=2.8%] for the treated group and 17.1% (SE=3.8%) for the non-treated group. The difference was statistically significant (p=0.01). By multivariate analysis, ZDV therapy and CD4 T-cell count >200/mm were the parameters independently associated with a slower progression to AIDS. Conclusions. Treatment with zidovudine seems to slow the progression to AIDS in HIV-positive hemophiliacs.

Cumulative incidence

Seroconversion

Source

Cite

Citations (2)

Replacement Therapy for Minor Surgery and Invasive Procedures in Factor VII Deficiency: The STER Experience

Blood (2011)

Mariasanta Napolitano Alberto Dolce Jørgen Ingerslev Muriel Giansily‐Blaizot Matteo ND Di Minno

Recombinant Factor VIIa

Factor VII

Fresh frozen plasma

Bleeding diathesis

10.1182/blood.v118.21.1262.1262

Cite

Citations (0)